News & Updates
Filter by Specialty:
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
Prasugrel appears to better protect against the risk of ischaemic events in patients with acute coronary syndrome (ACS) and prior myocardial infarction (MI) as compared with ticagrelor, without a trade-off in bleeding, a study has found.
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
24 Dec 2022
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
23 Dec 2022
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
23 Dec 2022
Serine protease inhibition shows promise in COVID-19
The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.
Serine protease inhibition shows promise in COVID-19
23 Dec 2022
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
